2 results
Approved WMORecruiting
The hypothesis is that the amivantamab and lazertinib combination (Arm A) will demonstrate superior PFS compared with single-agent osimertinib (Arm B).
Approved WMORecruiting
Primary objectives • To characterize the histamine dose response on pruritus• To profile the response to intradermal histamine by:o Clinical measureso Biophysical measureso Imagingo Molecular and cellular responsesSecondary objective • Comparison to…